This study revealed that the absence of KRAS mutation and presence of EGFR amplification may be potentially predictive molecular markers of the sensitivity of cholangiocarcinoma to EGFR-targeted therapy [32]. The gene discussed is EGFR; the disease is cholangiocarcinoma.